Ikena Oncology, Inc. (IKNA) Financial Statements (2024 and earlier)

Company Profile

Business Address 50 NORTHERN AVE.
BOSTON, MA 02210
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:70,86829,329156,90067,074192,81046,877
Cash and cash equivalents70,86829,32959,91967,07448,48746,877
Short-term investments   97,028 144,323 
Other undisclosed cash, cash equivalents, and short-term investments   (47)   
Prepaid expense1,578907271,4562,19719
Other current assets7311,4139641,1792,2961,050
Other undisclosed current assets87,469110,3461,419108,2691,842168,104
Total current assets:160,646141,178160,010177,978199,145216,050
Noncurrent Assets
Operating lease, right-of-use asset4,5754,9185,2555,5855,9106,226
Property, plant and equipment2,8753,1263,2053,1152,9502,292
Restricted cash and investments872872872872872872
Other undisclosed noncurrent assets2,7962,3072,9172,9182,3072,307
Total noncurrent assets:11,11811,22312,24912,49012,03911,697
TOTAL ASSETS:171,764152,401172,259190,468211,184227,747
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities4,7814,6245,8558,4308,2854,321
Employee-related liabilities2,7291,859930
Accounts payable1,7722,7592,0932,3614,0922,388
Accrued liabilities3,0091,8653,7623,3402,3341,003
Deferred revenue1,8443,8479,16012,10817,19416,749
Other liabilities10141193024316
Other undisclosed current liabilities5,3735,4656,3694,4722,7924,245
Total current liabilities:12,00813,95021,50325,04028,51425,331
Noncurrent Liabilities
Long-term debt and lease obligation   4,1384,4834,816
Long-term debt, excluding current maturities      
Liabilities, other than long-term debt3,0563,4293,7872,5023,8194,645
Deferred revenue    2,5023,8194,645
Operating lease, liability3,0563,4293,7874,1384,4834,816
Total noncurrent liabilities:3,0563,4293,7876,6408,3029,461
Total liabilities:15,06417,37925,29031,68036,81634,792
Equity
Equity, attributable to parent156,700135,022146,969158,788174,368192,955
Common stock423636363636
Additional paid in capital402,667363,915361,915360,055358,220355,690
Accumulated other comprehensive loss(456)(491)(763)(1,181)(1,104)(478)
Accumulated deficit(245,553)(228,438)(214,219)(200,122)(182,784)(162,293)
Other undisclosed equity      
Total equity:156,700135,022146,969158,788174,368192,955
TOTAL LIABILITIES AND EQUITY:171,764152,401172,259190,468211,184227,747

Income Statement (P&L) ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
Revenues2,0045,3135,4506,4023823,384
Gross profit:2,0045,3135,4506,4023823,384
Operating expenses(20,494)(20,828)(20,564)(24,278)(21,333)(20,346)
Operating loss:(18,490)(15,515)(15,114)(17,876)(20,951)(16,962)
Nonoperating income1,3751,2961,017538460123
Investment income, nonoperating1,381730    
Other nonoperating income (expense)(6)5661,017538460123
Loss from continuing operations:(17,115)(14,219)(14,097)(17,338)(20,491)(16,839)
Loss before gain (loss) on sale of properties:(17,338)(20,491)(16,839)
Net loss available to common stockholders, diluted:(17,115)(14,219)(14,097)(17,338)(20,491)(16,839)

Comprehensive Income ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
Net loss:(17,115)(14,219)(14,097)(17,338)(20,491)(16,839)
Other comprehensive income (loss)35272 (77)(626)(478)
Other undisclosed comprehensive income   763   
Comprehensive loss:(17,080)(13,947)(13,334)(17,415)(21,117)(17,317)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent   (55,013)17,33820,49116,839
Comprehensive loss, net of tax, attributable to parent:(17,080)(13,947)(68,347)(77)(626)(478)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: